4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.
Therapeutic subunit vaccines based on tumor-associated antigens (TAA) represent an attractive approach for the treatment of cancer. However, poor immunogenicity of TAAs requires potent adjuvants for therapeutic efficacy. We recently proposed the tumor necrosis factor family costimulatory ligands as potential adjuvants for therapeutic vaccines and, hence, generated a soluble form of 4-1BBL chimeric with streptavidin (SA-4-1BBL) that has pleiotropic effects on cells of innate, adaptive, and regulatory immunity. We herein tested whether these effects can translate into effective cancer immunotherapy when SA-4-1BBL was also used as a vehicle to deliver TAAs in vivo to dendritic cells (DCs) constitutively expressing the 4-1BB receptor. SA-4-1BBL was internalized by DCs upon receptor binding and immunization with biotinylated antigens conjugated to SA-4-1BBL resulted in increased antigen uptake and cross-presentation by DCs, leading to the generation of effective T-cell immune responses. Conjugate vaccines containing human papillomavirus 16 E7 oncoprotein or survivin as a self-TAA had potent therapeutic efficacy against TC-1 cervical and 3LL lung carcinoma tumors, respectively. Therapeutic efficacy of the vaccines was associated with increased CD4(+) T and CD8(+) T-cell effector and memory responses and higher intratumoral CD8(+) T effector/CD4(+)CD25(+)Foxp3(+) T regulatory cell ratio. Thus, potent pleiotropic immune functions of SA-4-1BBL combined with its ability to serve as a vehicle to increase the delivery of antigens to DCs in vivo endow this molecule with the potential to serve as an effective immunomodulatory component of therapeutic vaccines against cancer and chronic infections.
Sharma
Rajesh K
RK
Department of Microbiology and Immunology, James Brown Cancer Center, Institute for Cellular Therapeutics, University of Louisville and ApoImmune, Inc, Louisville, Kentucky, USA.
Schabowsky
Rich-Henry
RH
Srivastava
Abhishek K
AK
Elpek
Kutlu G
KG
Madireddi
Shravan
S
Zhao
Hong
H
Zhong
Zhenping
Z
Miller
Robert W
RW
Macleod
Kathryn J
KJ
Yolcu
Esma S
ES
Shirwan
Haval
H
D053330:4-1BB Ligand / Q000008:administration & dosage*; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D045142:Cross-Priming / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D050725:Papillomavirus E7 Proteins / Q000378:metabolism; D012097:Repressor Proteins; D015996:Survival Rate; D000077022:Survivin; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000628:therapy*
D053330:4-1BB Ligand; C117749:Birc5 protein, mouse; D019496:Cancer Vaccines; D007155:Immunologic Factors; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; D000077022:Survivin; C059731:oncogene protein E7, Human papillomavirus type 16
Int Immunol. 2006 Feb;18(2):325-33
16373363
Nat Rev Immunol. 2007 Oct;7(10):790-802
17853902
Science. 2007 Jan 5;315(5808):107-11
17204652
J Clin Immunol. 2007 Jul;27(4):363-71
17370119
Nat Immunol. 2006 Feb;7(2):165-72
16415871
J Immunol. 2007 Aug 1;179(3):1427-30
17641007
J Immunol. 2009 Apr 1;182(7):4107-15
19299708
J Immunol. 2006 Aug 15;177(4):2276-84
16887988
Int J Cancer. 1998 Sep 25;78(1):41-5
9724092
Cell Mol Immunol. 2004 Feb;1(1):71-6
16212924
J Immunol. 2002 May 1;168(9):4262-7
11970964
Exp Mol Pathol. 2009 Jun;86(3):198-207
19454266
J Exp Med. 1998 Jun 1;187(11):1849-62
9607925
Vaccine. 2009 Dec 11;28(2):512-22
19836479
J Clin Invest. 2008 Jun;118(6):2098-110
18497879
Nat Immunol. 2005 Dec;6(12):1219-27
16244650
Science. 2005 Mar 11;307(5715):1630-4
15761154
J Immunol. 2007 May 15;178(10):6259-67
17475854
Transplantation. 2005 Jun 15;79(11):1492-7
15940037
Int Immunol. 2002 Mar;14(3):275-86
11867564
Eur J Immunol. 2008 Oct;38(10):2678-88
18825741
J Immunol. 2007 May 1;178(9):5429-33
17442923
Nat Immunol. 2004 Nov;5(11):1143-8
15475958
Methods Enzymol. 1990;184:51-67
2388586
J Immunol. 2001 May 1;166(9):5327-30
11313367
Clin Cancer Res. 2003 Nov 1;9(14):5091-100
14613986
J Exp Med. 2000 Dec 18;192(12):1685-96
11120766
J Clin Invest. 2002 Jun;109(12):1519-26
12070296
J Exp Med. 2004 Mar 15;199(6):815-24
15024047
J Immunol. 2008 Apr 15;180(8):5267-74
18390707
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
16344461
Nat Med. 2004 Sep;10(9):942-9
15322536
J Immunol. 2001 May 1;166(9):5448-55
11313382
Diabetes. 2005 Dec;54(12):3395-401
16306354
Nat Rev Immunol. 2004 Jul;4(7):499-511
15229469
Cancer Res. 2009 May 15;69(10):4319-26
19435920
Nature. 2003 Feb 20;421(6925):852-6
12594515
J Clin Invest. 2002 Mar;109(5):651-9
11877473
J Exp Med. 1998 Dec 7;188(11):1977-83
9841912
J Exp Med. 2002 Dec 16;196(12):1627-38
12486105
Cancer Res. 2008 Jul 1;68(13):5206-15
18593921
J Biol Chem. 2005 Dec 16;280(50):41472-81
16204238
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5561-6
11929985
Annu Rev Immunol. 2005;23:23-68
15771565
Nat Rev Immunol. 2003 Aug;3(8):630-41
12974478
J Immunol. 2007 Dec 1;179(11):7295-304
18025172